LA
NKTR icon

LVW Advisors’s Nektar Therapeutics NKTR Stock Holding History

LVW Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Hold
3,022
– – 0.02% 441
2026
Q1 		$217K Buy
+3,022
New +$172K 0.02% 399

Other funds holding NKTR

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

LVW Advisors's NKTR Position: Q2 2026 in Review

LVW Advisors held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 3,022 shares worth $211K. The position accounts for 0.02% of the portfolio, ranked #441.

LVW Advisors first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. The position peaked at $217K in Q1 2026. 29 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • LVW Advisors held 3,022 shares of Nektar Therapeutics worth $211K as of Q2 2026.
  • LVW Advisors left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up 0.02% of LVW Advisors's portfolio in Q2 2026, its #441 holding.
  • LVW Advisors first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • LVW Advisors's Nektar Therapeutics position peaked at $217K in Q1 2026.
  • 29 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on LVW Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.